This company listing is no longer active
Acerus Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 0/6
Acerus Pharmaceuticals has a total shareholder equity of $-13.9M and total debt of $45.8M, which brings its debt-to-equity ratio to -329.8%. Its total assets and total liabilities are $47.7M and $61.6M respectively.
Informazioni chiave
-329.8%
Rapporto debito/patrimonio netto
US$45.82m
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | US$3.02m |
| Patrimonio netto | -US$13.89m |
| Totale passività | US$61.57m |
| Totale attività | US$47.67m |
Aggiornamenti recenti sulla salute finanziaria
Nessun aggiornamento
Recent updates
Analisi della posizione finanziaria
Passività a breve termine: ASPC.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passività a lungo termine: ASPC.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: ASPC.Q has negative shareholder equity, which is a more serious situation than a high debt level.
Riduzione del debito: ASPC.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: ASPC.Q has less than a year of cash runway based on its current free cash flow.
Previsione Cash Runway: ASPC.Q has less than a year of cash runway if free cash flow continues to reduce at historical rates of 45.6% each year